310 related articles for article (PubMed ID: 33249643)
1. Impact of Genetic and Pharmacologic Inhibition of Myostatin in a Murine Model of Osteogenesis Imperfecta.
Omosule CL; Gremminger VL; Aguillard AM; Jeong Y; Harrelson EN; Miloscio L; Mastaitis J; Rafique A; Kleiner S; Pfeiffer FM; Zhang A; Schulz LC; Phillips CL
J Bone Miner Res; 2021 Apr; 36(4):739-756. PubMed ID: 33249643
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial Inhibition of Myostatin and Activin A Improves Femoral Bone Properties in the G610C Mouse Model of Osteogenesis Imperfecta.
Omosule CL; Joseph D; Weiler B; Gremminger VL; Silvey S; Jeong Y; Rafique A; Krueger P; Kleiner S; Phillips CL
J Bone Miner Res; 2022 May; 37(5):938-953. PubMed ID: 35195284
[TBL] [Abstract][Full Text] [Related]
3. Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.
Jeong Y; Daghlas SA; Xie Y; Hulbert MA; Pfeiffer FM; Dallas MR; Omosule CL; Pearsall RS; Dallas SL; Phillips CL
J Bone Miner Res; 2018 Oct; 33(10):1760-1772. PubMed ID: 29813187
[TBL] [Abstract][Full Text] [Related]
4. Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice.
Oestreich AK; Carleton SM; Yao X; Gentry BA; Raw CE; Brown M; Pfeiffer FM; Wang Y; Phillips CL
Osteoporos Int; 2016 Jan; 27(1):161-70. PubMed ID: 26179666
[TBL] [Abstract][Full Text] [Related]
5. Hindlimb Skeletal Muscle Function and Skeletal Quality and Strength in +/G610C Mice With and Without Weight-Bearing Exercise.
Jeong Y; Carleton SM; Gentry BA; Yao X; Ferreira JA; Salamango DJ; Weis M; Oestreich AK; Williams AM; McCray MG; Eyre DR; Brown M; Wang Y; Phillips CL
J Bone Miner Res; 2015 Oct; 30(10):1874-86. PubMed ID: 25829218
[TBL] [Abstract][Full Text] [Related]
6. Soluble activin receptor type IIB decoy receptor differentially impacts murine osteogenesis imperfecta muscle function.
Jeong Y; Daghlas SA; Kahveci AS; Salamango D; Gentry BA; Brown M; Rector RS; Pearsall RS; Phillips CL
Muscle Nerve; 2018 Feb; 57(2):294-304. PubMed ID: 28555931
[TBL] [Abstract][Full Text] [Related]
7. Whole-Body Metabolism and the Musculoskeletal Impacts of Targeting Activin A and Myostatin in Severe Osteogenesis Imperfecta.
Omosule CL; Joseph D; Weiler B; Gremminger VL; Silvey S; Lafaver BN; Jeong Y; Kleiner S; Phillips CL
JBMR Plus; 2023 Jul; 7(7):e10753. PubMed ID: 37457877
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral properties in growing Col1a2(+/G610C) mice, an animal model of osteogenesis imperfecta.
Masci M; Wang M; Imbert L; Barnes AM; Spevak L; Lukashova L; Huang Y; Ma Y; Marini JC; Jacobsen CM; Warman ML; Boskey AL
Bone; 2016 Jun; 87():120-9. PubMed ID: 27083399
[TBL] [Abstract][Full Text] [Related]
9. Correlations Between Bone Mechanical Properties and Bone Composition Parameters in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-TGF-β Treatment.
Bi X; Grafe I; Ding H; Flores R; Munivez E; Jiang MM; Dawson B; Lee B; Ambrose CG
J Bone Miner Res; 2017 Feb; 32(2):347-359. PubMed ID: 27649409
[TBL] [Abstract][Full Text] [Related]
10. Skeletal muscle mitochondrial function and whole-body metabolic energetics in the +/G610C mouse model of osteogenesis imperfecta.
Gremminger VL; Omosule CL; Crawford TK; Cunningham R; Rector RS; Phillips CL
Mol Genet Metab; 2022 Aug; 136(4):315-323. PubMed ID: 35725939
[TBL] [Abstract][Full Text] [Related]
11. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.
Jacobsen CM; Barber LA; Ayturk UM; Roberts HJ; Deal LE; Schwartz MA; Weis M; Eyre D; Zurakowski D; Robling AG; Warman ML
J Bone Miner Res; 2014 Oct; 29(10):2297-306. PubMed ID: 24677211
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy in the Col1a2
Kaupp S; Horan DJ; Lim KE; Feldman HA; Robling AG; Warman ML; Jacobsen CM
Bone; 2020 Feb; 131():115084. PubMed ID: 31648079
[TBL] [Abstract][Full Text] [Related]
13. Early Fracture Healing is Delayed in the Col1a2
Besio R; Maruelli S; Battaglia S; Leoni L; Villani S; Layrolle P; Rossi A; Trichet V; Forlino A
Calcif Tissue Int; 2018 Dec; 103(6):653-662. PubMed ID: 30076439
[TBL] [Abstract][Full Text] [Related]
14. Novel ActRIIB ligand trap increases muscle mass and improves bone geometry in a mouse model of severe osteogenesis imperfecta.
Tauer JT; Rauch F
Bone; 2019 Nov; 128():115036. PubMed ID: 31419601
[TBL] [Abstract][Full Text] [Related]
15. Distinct type I collagen alterations cause intrinsic lung and respiratory defects of variable severity in mouse models of osteogenesis imperfecta.
Dimori M; Fett J; Leikin S; Otsuru S; Thostenson JD; Carroll JL; Morello R
J Physiol; 2023 Jan; 601(2):355-379. PubMed ID: 36285717
[TBL] [Abstract][Full Text] [Related]
16. Effect of rapamycin on bone mass and strength in the α2(I)-G610C mouse model of osteogenesis imperfecta.
Bateman JF; Sampurno L; Maurizi A; Lamandé SR; Sims NA; Cheng TL; Schindeler A; Little DG
J Cell Mol Med; 2019 Mar; 23(3):1735-1745. PubMed ID: 30597759
[TBL] [Abstract][Full Text] [Related]
17. Bone Marrow Transplantation for Treatment of the Col1a2
Lee LR; Peacock L; Ginn SL; Cantrill LC; Cheng TL; Little DG; Munns CF; Schindeler A
Calcif Tissue Int; 2019 Apr; 104(4):426-436. PubMed ID: 30535573
[TBL] [Abstract][Full Text] [Related]
18. Effect of Anti-TGF-β Treatment in a Mouse Model of Severe Osteogenesis Imperfecta.
Tauer JT; Abdullah S; Rauch F
J Bone Miner Res; 2019 Feb; 34(2):207-214. PubMed ID: 30357929
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta mice.
Wang L; Yu Y; Ni S; Li D; Liu J; Xie D; Chu HY; Ren Q; Zhong C; Zhang N; Li N; Sun M; Zhang ZK; Zhuo Z; Zhang H; Zhang S; Li M; Xia W; Zhang Z; Chen L; Shang P; Pan X; Lu A; Zhang BT; Zhang G
Theranostics; 2022; 12(13):5645-5674. PubMed ID: 35966595
[No Abstract] [Full Text] [Related]
20. Galunisertib downregulates mutant type I collagen expression and promotes MSCs osteogenesis in pediatric osteogenesis imperfecta.
Infante A; Alcorta-Sevillano N; Macías I; Cabodevilla L; Medhat D; Lafaver B; Crawford TK; Phillips CL; Bueno AM; Sagastizabal B; Arroyo M; Campino A; Gerovska D; Araúzo-Bravo M; Gener B; Rodríguez CI
Biomed Pharmacother; 2024 Jun; 175():116725. PubMed ID: 38744219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
